On Monday, December 9, from 6:30 to 7:30 p.m., immediately following the Special Symposium on the Basic Science of Hemostasis and Thrombosis, meeting attendees can gather to network with colleagues from the hemostasis and thrombosis community. This event encourages both clinicians and researchers to attend.

The reception will be held in the Sunburst Room (W340 – map it) of the Orange County Convention Center and is well known as an opportunity for hematologists of all levels to make new connections and reunite with old friends; however, it might be especially valuable for those new to hemostasis and thrombosis. “Junior faculty, fellows, and post-docs, as well as students interested in hemostasis and thrombosis can mingle with leaders in the field,” said Jorge Di Paola, MD, in a recent conversation with Robert Flaumenhaft, MD, PhD. “One thing that’s very positive about the hemostasis and thrombosis community is that it’s really a group of people that gets along really well,” said Dr. Flaumenhaft. “The reception works because it is such a welcoming community.”

Leading up to the reception is a special symposium developed by the Scientific Committees on Hemostasis, Thrombosis and Vascular Biology and Megakaryocytes and Platelets. The session, held on Monday from 4:30 to 6:30 p.m. (Tangerine 3 [WF3- 4], Level 2 [Orange County Convention Center] – map it) will highlight cutting-edge research and new basic science advances in areas of clinical importance.

Talks will include a discussion with David Lillicrap, MD, on the critical role of factor VIII (FVIII) and von Willebrand factor (VWF) in the hemostatic process. Aspects of the FVIII/VWF interaction will be highlighted. Subbian Ananth Karumanchi, MD, will discuss evidence suggesting that excess soluble fmslike tyrosine kinase1, an endogenous soluble inhibitor of VEGF signaling, may play a causal role in the pathogenesis of preeclampsia. Circulating levels of sFlt1 and placental growth factor PlGF, a ligand for sFlt1 may be used as markers for the early diagnosis of preeclampsia. Dr. Karumanchi will highlight novel treatments targeting sFlt1. Martha Sola-Visner, MD, will describe the growing body of evidence suggesting that neonatal megakaryopoiesis is characterized by a developmentally unique dissociation between proliferation, polyploidization and maturation, challenging the paradigm that neonatal megakaryocytes and platelets are simply “immature.”

Additionally, Oluwatoyosi Muse, PhD, the winner of the Mary Rodes Gibson Memorial Award, will present her award-winning abstract, “The Unfolded Protein Response Causes Prothrombotic Transformation of Pancreatic Cancer Linking Tumor Progression with Cancer-Associated Thrombosis,” at the symposium.

Don’t miss these two events made especially for and by the hemostasis and thrombosis community.


Learn More

Interested attendees can register for the event at https://na.eventscloud.com/ereg/index.php?eventid= 462122&.


Share This